ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ubamatamab

Its studies are mostly in Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Regeneron Pharmaceuticals.

Drug pageUbamatamab: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jan 16, 20252 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals22 open or runningphase 2since Jan 16, 2025Jan 16, 2025Jun 30, 2028phase 2 · NCT06787612

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named ubamatamabINNProposed as its International Nonproprietary Name in WHO's List 125
  2. Jan 16, 2025First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT06787612 · 397 planned · United States, Canada, South Korea and more
  3. Aug 26, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07154290 · 300 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT06787612
  2. Jun 10, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07154290

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07154290Carcinoma, Non-Small-Cell Lung · United States2RecruitingJun 10, 2030300
NCT06787612Ovarian Neoplasms · United States, Canada, South Korea and more2RecruitingJun 30, 2028397

How it is read

Names in the registry

  • “Ubamatamab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.